Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Trial end date:
2011-01-18
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for
their growth. Giving erlotinib after chemoradiotherapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of adjuvant erlotinib
when given after completing chemoradiotherapy in treating patients with locally advanced
squamous cell carcinoma (cancer) of the head and neck.